Skip to main content
SpringerLink
Log in

Authors’ Reply to Ravi Jandhyala’s Comment on “Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments”

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 24 September 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McGettigan P, Alonso CO, Plueschke K, Castillon M, Nogueras DZ, Bahri P, et al. Patient registries: an underused resource for medicines evaluation: operational proposals for increasing the use of patient registries in regulatory assessments. Drug Saf. 2019. https://doi.org/10.1007/s40264-019-00848-9.

    Article  PubMed  Google Scholar 

  2. Jandhyala R. Comment on: "Patient registries: an underused resource for medicines evaluation: operational proposals for increasing the use of patient registries in regulatory assessments". Drug Saf. 2019. https://doi.org/10.1007/s40264-019-00862-x.

    Article  PubMed  Google Scholar 

  3. Pacurariu A, Plueschke K, Olmo CA, Kurz X. Imposed registries within the European postmarketing surveillance system: extended analysis and lessons learned for regulators. Pharmacoepidemiol Drug Saf. 2018;27(7):823–6.

    Article  Google Scholar 

  4. Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiol Drug Saf. 2017;26(12):1442–50.

    Article  Google Scholar 

  5. Olmo CA, McGettigan P, Kurz X. Barriers and opportunities for use of patient registries in medicines regulation. Clin Pharmacol Ther. 2019;106(1):39–42.

    Article  Google Scholar 

  6. Bearman M, Dawson P. Qualitative synthesis and systematic review in health professions education. Med Educ. 2013;47:252–60.

    Article  Google Scholar 

  7. European Medicines Agency. Patient registries. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/patient-registries. Accessed 18 Sep 2019.

  8. Lauer MS, D’Agostino RB. The randomized registry trial—the next disruptive technology in clinical research? N Engl J Med. 2013;369(17):1579–81.

    Article  CAS  Google Scholar 

  9. Li G, Sajobi TT, Menon BL, et al. Registry-based randomized controlled trials—what are the advantages, challenges, and areas for future research? J Clin Epidemiol. 2016;80:16–24.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London, UK

    Patricia McGettigan

  2. Pharmacovigilance and Epidemiology Department, European Medicines Agency, Amsterdam, The Netherlands

    Carla Alonso Olmo, Kelly Plueschke, Mireia Castillon, Daniel Zondag, Priya Bahri & Xavier Kurz

  3. Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

    Peter G. M. Mol

  4. Dutch Medicines Evaluation Board, Utrecht, The Netherlands

    Peter G. M. Mol

Authors
  1. Patricia McGettigan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carla Alonso Olmo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kelly Plueschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mireia Castillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniel Zondag
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Priya Bahri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xavier Kurz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Peter G. M. Mol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patricia McGettigan.

Ethics declarations

Funding

This work was not funded.

Conflict of interest

Patricia McGettigan, Carla Alonso Olmo, Kelly Plueschke, Mireia Castillon, Daniel Zondag, Priya Bahri, Xavier Kurz and Peter Mol have no conflicts of interest that are directly relevant to the content of this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McGettigan, P., Olmo, C.A., Plueschke, K. et al. Authors’ Reply to Ravi Jandhyala’s Comment on “Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments”. Drug Saf 42, 1517–1518 (2019). https://doi.org/10.1007/s40264-019-00863-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-019-00863-w

Search

Navigation